ARTICULOS ORIGINALES

 

Inactivación viral en el Intacglobín por el pH y la temperatura.

 

Viral Inactivation by pH and Temperature in Intaglobin preparations.

Armando Cádiz1, María Esther Castellano2, Dalia Rodríguez3, Rosa Iris Reina2, Janhna Hernández1, Alexandro Rodríguez4, Aniel Moya1.

1 Instituto Finlay, Centro de Investigación-Producción de Vacunas y Sueros. Ciudad de La Habana, Cuba.
E-mail:[e-mail]

2 Planta de Hemoderivados. Ciudad de La Habana, Cuba.

3 Instituto Nacional de Medicina Veterinaria. Ciudad de La Habana, Cuba.

4 Dpto. Inmunología ICBP Victoria de Girón. Ciudad de La Habana, Cuba

---

RESUMEN

Se utilizó la Encefalomiocarditis (EMC) porcina como virus modelo en el estudio de inactivación viral en el proceso de producción de un preparado de inmunoglobulina humana para uso intravenoso, para lo que se escogieron dos variables a tener en cuenta: el pH y la temperatura; preparándose cuatro grupos experimentales: pH ácido (4,3) y temperatura 5 °C, pH ácido (4,3) y temperatura 28 °C, pH básico (7,0) y temperatura 5 °C y por último pH básico (7,0) y temperatura 28 °C. Para cada caso se tomaron muestras a diferentes tiempos para conocer el grado de inactivación viral. Los mejores resultados en cuanto a la disminución de la infectividad, se obtuvieron para las muestras tratadas con pH 4,3 y temperatura 28 °C, mostrándose la total inactivación del virus, a partir de las 8 h. En las muestras tratadas bajo las otras condiciones, solo se observó la completa inactivación viral a partir de las cinco semanas. Verificamos que las características organolépticas y químicas del producto se mantuvieran inalterables durante el transcurso de las ocho semanas que duró el experimento.Llegamos a conclusiones acerca de que el pH ácido y las altas temperaturas, así como el tiempo de incubación, son variables importantes en la cinética de inactivación viral.

Palabras claves: Inmunoglobulina intravenosa, inactivación viral, pH y temperatura.

---

ABSTRACT

Swine encephalomyocarditis (SE) was used as a model virus to study viral inactivation in the production process of a human immunoglobulin preparation for intravenous use. Two variables were selected for this: ph and temperature. Four experimental groups were prepared: acid pH (4,3) and 5 °C temperature, acid pH (4,3) and 28 °C temperature, basic pH (7,0) and 5 °C temperature and basic pH (7,0) and 28 °C temperature. In each case, to determine the rate of viral inactivation, samples were taken at different times. The best results with respect to decreasing infectivity were obtained for the samples treated with 4,3 pH and 28 °C temperature, with a total inactivation of the virus after 8 hours. In the samples treated under the other conditions, complete viral inactivation was only observed after 5 weeks. We checked that the chemical and organoleptic characteristics of the product remained unchanged during the 8 weeks the experiment lasted. We concluded that acid pH and high temperatures, as well as the incubation time are important variables in the viral inactivation kinetics.

Keywords: Intravenous immunoglobulin, viral inactivations, pH and temperature.

---

Texto completo en pdf

REFERENCIAS

1. Gao F, Prince A, Pascual D, Horowitz B. Enhancement in the Safety of Immune Globulins Prepared from High-Risk Plasma.Vox Sang 1993; 64:204-209.

2. Dodd R. Infectious risk of plasma donations: relationship to safety of intravenous immune globulins.Clin Exp Immunol 1996; 104 (Suppl. 1):3-4.

3. Siegel J. Viral Safety Issues in IVIG Products. Safety Issues.P &T 1996; 21-241

4. Brenner B. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin. Clinical and Experimental Rheumatology 1996, 14 (Suppl. 15): S115-S119.

5. Yap, PL. Viral safety of IVIG. In: Intravenous Immunoglobulins in clinical practice. Martin Lee y Vibeke Stand ed. NY, USA: Marcel Dekker Inc 1997; 601-616.

6. Bos O. Virus Validation of pH 4 _ treated Human Immunoglobulin Products Produced by the Cohn Fractionation Process.Biologicals 1998; 26:267_276.

7. Troccoli N. Removal of Viruses from Human Intravenous Immune Globulin by 35 nm Nanofiltration.Biologicals 1998; 26:321-329.

8. EEC. Regulatory Document. Comittee for proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology / Pharmacy and Working Party on Safety Medicines. Validation of virus removal and inactivation procedures. Biologicals. 1991; 19:24-25.

9. Grun BJ. Viral removal / inactivation by purification of biopharmaceutical.Biopharm 1992; 5 (9):22_30.

10. European Plasma Fractionation Association (EPFA) and European Association of the Plasma Products Industries (EAPPI ). Points to consider on virus safe plasma products. CPMP ad hoc Working Party on Biotechnology / Pharmacy (1994).Biologicals 1995; 23:193-195.

11. White E. Process validation for virus removal and inactivation. Biopharm 1991; 4 (5): 34-39.

12. Reed LJ, Muench H. A simple method of estimating fifty percent endpoint.Amer J Hyg 1938; 27:493-497.

13. Comittee Propietary Medical Products (CPMP). Biotechnology Working Party. Note for guidance on virus validation studies: the desing, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP / BWP / 268 / 95. Final version - 2, 1996.

14. Hageman TC. Philosophy and goals of validation for biotech and relevance of scale.Dev Biol Stand 1992, 76:231-237.

15. PDA. Industry perspective on the validation of column - based separation process for purification of protein. Journal of Parenteral Science and Technology 1992; 46(3):87_97.

16. Morales A. Estudio preliminar de diferentes parámetros para la inactivación de virus en el Intacglobin. Trabajo de Diploma. Facultad de Farmacia y Alimentos. Universidad de La Habana. Ciudad de La Habana, 1996.

17. O´Nell PF, Balkovic ES. Virus harvesing and affinity - based liquid chromatography. Biotechnology 1993; 11:173-7.

18. WHO / LBS. Global Blood safety initiative. Viral inactivation of blood and blood products. Prepared on behalf of the WHO by Dr. H. Soumela, Finnish Red Cross Blood Transfussion Servis, Helsinki, Filand. 1992.

19. Nowat T; Gregersen P; Klockmann U; Cummins L. Virus Safety of Human Immunoglobulins: Efficient Inactivation of Hepatitis C and Other Human Pathogenic Viruses by the Manufacturing Procedure.Journal of Medical Virology 1992; 36:209-216.

20. Hernández J. Simplificación del proceso de producción del Intacglobín y seguridad en la transmisión de virus. Trabajo de Diploma, Universidad de La Habana, 1997.

21. Uemura Y. Inactivation and elimination of virus during the fractionation of an Intravenous Immunoglobulin Preparation: Liquid Heat Treatment and Polyethylene Glycol fractionation.Vox Sang 1989; 56:155-61.

22. Bridoneau P. Liquid Pasteurization of an Immunoglobulin Preparation without atabilizer: Effects on its Biological and Biochemical Properties.Vox Sang. 1996; 70:203-209.

23. Cádiz A; Castellano ME; Hernández J; Castillo JR; Mustelier P; Ramirez A. Influencia del pH sobre la estabilidad de preparados de inmunoglobulinas intravenosas para uso humano durante el almacenamiento.Vaccimonitor 2000; 9:21-25.

24. Uemura Y. Dissociation of Agregated IgG and Denaturation of Monomeric IgG by Acid Treatment.Journal Medicine 1983; 141:337-349.